Snapshot from Aug 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / ETH Zurich breath acetone detector
Tech medical breakthrough

ETH Zurich breath acetone detector

Analysis based on 9 articles · First reported Jul 22, 2026 · Last updated Jul 23, 2026

Sentiment
30
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The breath acetone detector represents a non-invasive, user-friendly tool for metabolic monitoring, potentially disrupting the market for glucose and ketone testing. It could drive growth in the medical device and digital health sectors, though commercialization is still early-stage.

medical devices healthcare biotechnology
Event Summary

Researchers from ETH Zurich have developed a portable, smartphone-assisted breath acetone detector that measures fat metabolism with laboratory-level accuracy. The device, commercialized by ETH spin-off Alivion AG under the name 'Nutrion', detects acetone in exhaled breath, a by-product of fat burning. In a validation study with 12 adults, 312 breath readings closely matched mass spectrometry results. The technology could enable personalized monitoring of diets, metabolic disorders like diabetes, and ketogenic therapies for epilepsy. The device is currently used in clinical studies at University Children s Hospital Zurich and by individuals for weight loss and athletic performance. The research was published in the journal Device on July 22, 2026, and supported by Switzerland — Innosuisse, Tax Foundation, and Accentus Foundation.

Key Actions
60 Alivion commercialized
Entities Involved
priv
Alivion
Alivion commercialized the device as 'Nutrion', positioning itself in the metabolic monitoring market and seeking investors.
Importance 80.0 Sentiment 60.0
per
Andreas Güntner
Lead researcher; his group's work advances personalized medicine and may lead to spin-off success.
Importance 70.0 Sentiment 20.0
per
Simone Hersberger
First author of the study; contributed to device development and validation.
Importance 40.0 Sentiment 10.0
priv
University Children s Hospital Zurich
Conducting clinical studies using the device for epilepsy patients.
Importance 25.0 Sentiment 10.0
govactor
Switzerland — Innosuisse
Provided funding, supporting innovation in Swiss medtech.
Importance 20.0 Sentiment 5.0
ngo
Tax Foundation
Financial supporter of the research.
Importance 15.0 Sentiment 5.0
ngo
Accentus Foundation
Financial supporter of the research.
Importance 15.0 Sentiment 5.0
priv
Cell Press
Published the study in its journal Device, adding credibility.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.